Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131)

Engaging inhibitory FcγRIIb by Fc region has been recently reported to be an attractive approach for improving the efficacy of antibody therapeutics. However, the previously reported S267E/L328F variant with enhanced binding affinity to FcγRIIb, also enhances binding affinity to FcγRIIa(R131) alloty...

Descripción completa

Detalles Bibliográficos
Autores principales: Mimoto, F., Katada, H., Kadono, S., Igawa, T., Kuramochi, T., Muraoka, M., Wada, Y., Haraya, K., Miyazaki, T., Hattori, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785249/
https://www.ncbi.nlm.nih.gov/pubmed/23744091
http://dx.doi.org/10.1093/protein/gzt022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785249/
https://www.ncbi.nlm.nih.gov/pubmed/23744091
http://dx.doi.org/10.1093/protein/gzt022

Ejemplares similares